Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice

Journal of Pharmacological Sciences

Volumn 120, Issue 1, 2012, Pages 36-44

  Tahara, Atsuo ^a   Kurosaki, Eiji ^a   Yokono, Masanori ^a   Yamajuku, Daisuke ^a   Kihara, Rumi ^a   Hayashizaki, Yuka ^a   Takasu, Toshiyuki ^a   Imamura, Masakazu ^a   Qun, Li ^b   Tomiyama, Hiroshi ^c   Kobayashi, Yoshinori ^d   Noda, Atsushi ^d   Sasamata, Masao ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c Research and Development Department   (Japan)

^d Kotobuki Pharmaceutical Co Ltd   (Japan)

Author keywords

Diabetes; Hyperglycemia; Ipragliflozin; SGLT2; Urinary glucose excretion

Indexed keywords

INSULIN; IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; EVENING DOSAGE; GLUCOSE ABSORPTION; GLUCOSE INTOLERANCE; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST;

EID: 84866541730     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12089FP     Document Type: Article

References (29)

1. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106:329-333.
2. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11:79-88.
3. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447:510-518.
4. Pajor AM, Wright EM. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem. 1992;267:3557-3560.
5. Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354-356.
6. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992;263:F459-F465.
7. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002;111: 544-547.
8. Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism. 1990;39:787-793.
9. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79:1510-1515.
10. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1991;87:561-570.
11. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31-38.
12. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48:1794-1800.
13. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57: 1723-1729.
14. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012;385: 423-436.
15. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M. Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice. Horm Metab Res. 2008;40:880-886.
16. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology. 2009; 83:177-187.
17. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009;609:148-154.
18. Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, Matsumoto M, et al. Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem. 1999;42:5311-5324.
19. van den Arend IJ, Stolk RP, Krans HM, Grobbee DE, Schrijvers AJ. Management of type 2 diabetes: a challenge for patient and physician. Patient Educ Couns. 2000;40:187-194.
20. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
21. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev. 1994;10:31-43.
22. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15:297-303.
23. Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, et al. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism. 2009;58:379-386.
24. Hosokawa YA, Leahy JL. Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes. 1997;46:808-813.
25. Leahy JL. Beta-cell dysfunction with chronic hyperglycemia: "overworked beta-cell" hypothesis. Diabetes Rev. 1996;4:298-319.
26. Taverna MJ, Pacher N, Bruzzo F, Slama G, Selam JL. Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes. Diabet Med. 2001;18: 584-588.
27. Kawaki J, Nagashima K, Tanaka J, Miki T, Miyazaki M, Gonoi T, et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes. 1999;48:2001-2006.
28. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510-516.
29. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20:1645-1652.